Factors associated with elevated SARS-CoV-2 immune response in children and adolescents DOI Creative Commons
Sarah Messiah,

Rhiana A. Abbas,

Emma Bergqvist

et al.

Frontiers in Pediatrics, Journal Year: 2024, Volume and Issue: 12

Published: Aug. 15, 2024

Background Understanding the distinct immunologic responses to SARS-CoV-2 infection among pediatric populations is pivotal in navigating COVID-19 pandemic and informing future public health strategies. This study aimed identify factors associated with heightened antibody children adolescents potential unique immune dynamics this population. Methods Data collected between July December 2023 from Texas Coronavirus Antibody REsponse Survey (Texas CARES), a statewide prospective population-based survey 1-to-19-year-old participants, were analyzed. Each participant had following data available for analysis: (1) Roche Elecsys® Anti-SARS-CoV-2 Immunoassay Nucleocapsid protein antibodies (Roche N-test), (2) qualitative semi-quantitative detection of SARS CoV-2 spike receptor binding domain S-test), (3) self-reported antigen/PCR test results, vaccination, status. Statistical analysis identified associations characteristics quartile group. Results The analytical sample consisted 411 participants (mean age 12.2 years, 50.6% female). Spike values ranged low 6.3 U/ml lowest maximum 203,132.0 highest aggregate sample. Older at date (OR = 1.22, 95% CI: 1.12, 1.35, p < .001) vaccination status (primary series/partially vaccinated, one or multiple boosters) showed significantly higher odds being compared younger unvaccinated Conversely, fewer days since last immunity challenge decreased 0.98, 0.96, 0.99, 0.002) vs. more challenge. Additionally, out every three infections asymptomatic. Conclusions age, duration (vaccine infection), responses, highlighting nuanced A significant proportion children/adolescents continue have asymptomatic infection, which has important implications.

Language: Английский

COVID-19 symptom severity and duration among outpatients, July 2021-May 2023: The PROTECT observational study DOI Creative Commons

Bhavya Vashi,

Kristen Pettrone, Claire Wilson

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0314518 - e0314518

Published: Feb. 21, 2025

Introduction With the emergence of new SARS-CoV-2 variants has come significant variations in disease manifestation, severity, and duration non-hospitalized infected patients. To characterize symptom patterns risk factors associated with severity duration, COVID-19 influenza-like illness (ILI) outpatients their contacts were enrolled at two sites United States America one site Thailand. Methods infection was confirmed enrollment a positive antigen or PCR test. Baseline demographics medical histories collected from participants daily self-reported questionnaires obtained to assess duration. Risk determined by multivariate logistic regression Cox proportional hazards model. Results Two hundred forty meeting eligibility criteria enrolled, including 174 cases (9% Delta 90% Omicron), 33 ILI cases, 34 healthy contacts. had shorter median 9.0 (95% CI, 8.0–11.0) days than participants. Infection variant resulted longer alleviation period compared Omicron variant. The most commonly reported symptoms among nasal chest/respiratory domains FLU-PRO Plus. Participants more overall, significantly affecting eyes senses reported. 55% SARS-CoV-2-positive reached negative N1 Ct value day 14 study time point. No for moderate severe identified this outpatient cohort. Male sex Conclusion Symptom manifestation varied variants. Few increased

Language: Английский

Citations

0
Estimate the Numbers of Lives Saved by a SARS-CoV-2 Vaccination Campaign in Six States in the United States with a Simple Model DOI Creative Commons
Yin Yi,

Shuhan Tang,

Qiong Li

et al.

IJID Regions, Journal Year: 2024, Volume and Issue: 12, P. 100390 - 100390

Published: June 15, 2024

Vaccination and the emergence of highly transmissible Omicron variant changed fate COVID-19 pandemic. It is very challenging to estimate number lives saved by vaccination given multiple doses vaccination, time-varying nature transmissibility, waning immunity, presence immune evasion. We established a S-SV-E-I-T-D-R model simulate numbers in six states United States during March 5, 2020, 23, 2023. The cumulative deaths were estimated under three scenarios based on two assumptions. Additionally, evasion loss protection afforded or infection considered. averted vaccinations (including doses) was ranged from 0.154% 0.295% total population across states. third 0.008% 0.017% population. Our death U.S. largely line with official (at level 0.15%-0.20% population). found that additional contribution small but significant.

Language: Английский

Citations

0
Duration of Postvaccination Neutralizing Antibodies to SARS‐CoV‐2 and Medication Effects: Results from the Safety and Immunogenicity of COVID‐19 Vaccination in Systemic Immune‐Mediated Inflammatory Diseases Cohort Study DOI Creative Commons

Rami Habib,

Roya M. Dayam,

Carol Hitchon

et al.

ACR Open Rheumatology, Journal Year: 2024, Volume and Issue: 6(9), P. 581 - 586

Published: July 1, 2024

In the face of ongoing circulation SARS-CoV-2, durability neutralization post-COVID-19 vaccination in immune-mediated inflammatory disease (IMID) is a key issue, as are effects medications.

Language: Английский

Citations

0
Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States DOI Creative Commons
Ana Carolina Mourão Toreli, Marisol Miranda Galvis, Muhannad Sharara

et al.

Leukemia & lymphoma/Leukemia and lymphoma, Journal Year: 2024, Volume and Issue: 65(11), P. 1706 - 1715

Published: July 5, 2024

This study investigates COVID-19 outcomes and immune response in chronic myeloid leukemia (CML) patients post-SARS-CoV-2 vaccination, comparing effectiveness of various vaccine options. Data from 118 CML (85 Brazil, 33 the US) showed similar infection rates prior (14% 9.1% post-vaccination (24.7% vs. 27.3%, respectively). In AstraZeneca CoronaVac were most commonly used brands, while US, Moderna Pfizer-BioNTech vaccines dominated. Despite lower seroconversion Brazilian cohort, all five brands analyzed prevented severe COVID-19. Patients who received mRNA recombinant viral vector (HR: 2.20; 95%CI 1.07–4.51; p < .031) those that had achieved at least major molecular 1.51; 95% CI 1.01–3.31; .0001) higher rates. Our findings suggest can generate antibody responses regardless brand, thereby mitigating effect is more pronounced with well-controlled disease.

Language: Английский

Citations

0
Factors associated with elevated SARS-CoV-2 immune response in children and adolescents DOI Creative Commons
Sarah Messiah,

Rhiana A. Abbas,

Emma Bergqvist

et al.

Frontiers in Pediatrics, Journal Year: 2024, Volume and Issue: 12

Published: Aug. 15, 2024

Background Understanding the distinct immunologic responses to SARS-CoV-2 infection among pediatric populations is pivotal in navigating COVID-19 pandemic and informing future public health strategies. This study aimed identify factors associated with heightened antibody children adolescents potential unique immune dynamics this population. Methods Data collected between July December 2023 from Texas Coronavirus Antibody REsponse Survey (Texas CARES), a statewide prospective population-based survey 1-to-19-year-old participants, were analyzed. Each participant had following data available for analysis: (1) Roche Elecsys® Anti-SARS-CoV-2 Immunoassay Nucleocapsid protein antibodies (Roche N-test), (2) qualitative semi-quantitative detection of SARS CoV-2 spike receptor binding domain S-test), (3) self-reported antigen/PCR test results, vaccination, status. Statistical analysis identified associations characteristics quartile group. Results The analytical sample consisted 411 participants (mean age 12.2 years, 50.6% female). Spike values ranged low 6.3 U/ml lowest maximum 203,132.0 highest aggregate sample. Older at date (OR = 1.22, 95% CI: 1.12, 1.35, p &lt; .001) vaccination status (primary series/partially vaccinated, one or multiple boosters) showed significantly higher odds being compared younger unvaccinated Conversely, fewer days since last immunity challenge decreased 0.98, 0.96, 0.99, 0.002) vs. more challenge. Additionally, out every three infections asymptomatic. Conclusions age, duration (vaccine infection), responses, highlighting nuanced A significant proportion children/adolescents continue have asymptomatic infection, which has important implications.

Language: Английский

Citations

0